N-(3-methoxy-5-nitro-phenyl)-dimethyl-amine | 350800-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-methoxy-5-nitro-phenyl)-dimethyl-amine
• 英文别名: N,N-dimethyl-3-methoxy-5-nitroaniline；(3-Methoxy-5-nitro-phenyl)-dimethylamine；3-methoxy-N,N-dimethyl-5-nitroaniline
• CAS: 350800-67-8
• 化学式: C₉H₁₂N₂O₃
• 分子量: 196.206
• InChiKey: WEBNTKILZTVPBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-methoxy-5-nitro-phenyl)-dimethyl-amine 在 palladium on activated charcoal 氢气 作用下， 反应 16.0h， 生成 5-methoxy-N,N-dimethyl-benzene-1,3-diamine
  参考文献：
  名称：

  Theramutein modulators

  摘要：

  这项发明涉及的是抑制或激活内源性蛋白变异形式的试剂以及识别这些变异的新方法。特别感兴趣的是那些由突变基因编码的内源性蛋白变异的抑制剂和激活剂，这些变异通常是在暴露于已知是相应未突变内源性蛋白的抑制剂或激活剂的化学试剂之后出现，或者至少是首次被识别为由此类化学试剂引起的。

  公开号：

  US20100016298A1
• 作为产物：
  描述：

  3-甲氧基-5-硝基苯胺 、 硫酸二甲酯 在 sodium hydroxide 作用下， 以 氯苯 、 水 为溶剂， 反应 48.0h， 以63.6%的产率得到N-(3-methoxy-5-nitro-phenyl)-dimethyl-amine
  参考文献：
  名称：

  Coupling compounds and hair dyeing compositions containg them

  摘要：

  本发明涉及式(I)化合物，其中X为氧或硫；R1为(C1-C4)烷基、被羟基取代的(C1-C4)烷基、(C1-C4)烷氧基、羟基-(C1-C4)烷氧基、氰基、-COOR6、-CON(R6)2或-N(R6)2或为苯基；R2为氢、甲基或乙基；R3为氢、(C1-C4)烷基磺酰基、被羟基、卤素、氰基、(C1-C4)烷氧基或-N(R6)2取代的(C1-C4)烷基磺酰基，或为-SO2-CH=CH2、-SO2N(R6)2或-PO(OR6)2；或者，当R4和R5不为氢时，R3为羟基-(C1-C4)烷基；R4为氢、(C1-C4)烷基、被羟基、(C1-C4)烷氧基或羟基-(C1-C4)烷氧基取代的(C1-C4)烷基；R5为氢、(C1-C4)烷基、被羟基、(C1-C4)烷氧基或羟基-(C1-C4)烷氧基取代的(C1-C4)烷基；R6为氢、(C1-C4)烷基或羟基-(C1-C4)烷基；其中R3、R4和R6均为氢或不同，并且式(I)化合物中R1为甲基且R2至R5均为氢的化合物除外，以及含有它们的染发组合物。

  公开号：

  EP1847526A1

文献信息

• Theramutein modulators
  申请人：Housey Gerad M.

  公开号：US20100016298A1

  公开（公告）日：2010-01-21

  This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

  这项发明涉及的是抑制或激活内源性蛋白变异形式的试剂以及识别这些变异的新方法。特别感兴趣的是那些由突变基因编码的内源性蛋白变异的抑制剂和激活剂，这些变异通常是在暴露于已知是相应未突变内源性蛋白的抑制剂或激活剂的化学试剂之后出现，或者至少是首次被识别为由此类化学试剂引起的。
• N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20070099877A1

  公开（公告）日：2007-05-03

  Disclosed are N-aryl-thienopyrimidin-4-amines and analogs thereof, represented by the Formulae I-II: wherein Ar and R 1 -R 4 are defined herein. The present invention relates to the discovery that compounds having Formulae I-II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  揭示了N-芳基噻吩吡嘧啶-4-胺及其类似物，由以下的式子I-II表示：其中Ar和R1-R4在此有所定义。本发明涉及发现具有式子I-II的化合物是半胱氨酸蛋白酶的激活剂和凋亡诱导剂。因此，本发明的半胱氨酸蛋白酶激活剂和凋亡诱导剂可用于诱导在各种临床病况中发生细胞死亡，这些病况中存在细胞不受控制的生长和异常细胞的扩散。
• Template Synthesis to Solve the Unreachable <i>Ortho</i> C–H Functionalization Reaction of Aryl Iodide
  作者：Bo-Sheng Zhang、Wan-Yuan Jia、Yi-Ming Wang、João C. A. Oliveira、Svenja Warratz、Ze-Qiang Zhang、Xue-Ya Gou、Yong-Min Liang、Xi-Cun Wang、Zheng-Jun Quan、Lutz Ackermann

  DOI：10.1021/acs.joc.3c02014

  日期：2023.12.1

  This report describes the use of a simple Pd/NBE catalytic system to achieve ortho C–H oxylation and phosphonylation and other functionalizations of aryl iodide through templated conversion reactions. Dimethylamine is introduced in the ortho-site of aryl iodide through C–H amination, and aryl dimethylamine is quickly converted to methyl quaternary ammonium salt precipitation. Methyl quaternary ammonium

  该报告描述了使用简单的 Pd/NBE 催化系统通过模板转化反应实现芳基碘的邻位C-H 氧基化和膦酰化以及其他功能化。通过C-H胺化在芳基碘化物的邻位引入二甲胺，芳基二甲胺迅速转化为甲基季铵盐沉淀。甲基季铵盐避免了后续官能化中的霍夫曼消除。该方法间接解决了Pd/NBE化学领域长期以来未能实现的各种芳基碘化物邻位官能化反应。
• Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
  申请人：HMI Medical Innovations, LLC

  公开号：US10018619B2

  公开（公告）日：2018-07-10

  This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

  本发明涉及鉴定、合成、优化和剖析作为蛋白质抑制剂或激活剂的化合物的方法，这些蛋白质既包括天然存在的内源性蛋白质，也包括内源性蛋白质的某些变体形式，以及鉴定这些变体的新方法。该方法通过改进新药鉴定、先导物优化、生物分析和快速消除有毒化合物，简化了药物发现和创造过程，从而加快了作为潜在治疗药物的化合物的鉴定和开发。该方法的实施可相应提高效率，从而降低药物发现过程的总体成本。
• Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
  申请人：HMI Medical Innovations, LLC

  公开号：US10473643B2

  公开（公告）日：2019-11-12

  This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

  本发明涉及鉴定、合成、优化和剖析作为蛋白质抑制剂或激活剂的化合物的方法，这些蛋白质既包括天然存在的内源性蛋白质，也包括内源性蛋白质的某些变体形式，以及鉴定这些变体的新方法。该方法通过改进新药鉴定、先导物优化、生物分析和快速消除有毒化合物，简化了药物发现和创造过程，从而加快了作为潜在治疗药物的化合物的鉴定和开发。该方法的实施可相应提高效率，从而降低药物发现过程的总体成本。